Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:				
Name:	Name:				
Ward:	NHI:				
Pneumococcal (PCV13) conjugate vaccine					
INITIATION – Primary course for previously unvaccinated child Re-assessment required after 3 doses Prerequisites (tick box where appropriate) A primary course of three doses for previously unvaccinate					
INITIATION – High risk individuals who have received PCV10 Re-assessment required after 2 doses Prerequisites (tick box where appropriate) Two doses are funded for high risk individuals (over the agriculture) primary course of PCV10	ge of 12 months and under 18 years) who have previously received two doses of the				
INITIATION – High risk children aged under 5 years Re-assessment required after 4 doses Prerequisites (tick boxes where appropriate)					
Up to an additional four doses (as appropriate) are f	funded for the (re)immunisation of high-risk children aged under 5 years				
	On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response				
Or Primary immune deficiencies	Primary immune deficiencies				
O HIV infection	HIV infection				
O Renal failure, or nephrotic syndrome	Renal failure, or nephrotic syndrome				
	Are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant)				
O Cochlear implants or intracranial shunts	O Cochlear implants or intracranial shunts				
O Cerebrospinal fluid leaks					
	n two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg e than 10 kg on a total daily dosage of 20 mg or greater				
	treated with high-dose corticosteroid therapy)				
O Pre term infants, born before 28 weeks gestat	ion				
O Cardiac disease, with cyanosis or failure					
Or Diabetes					
O Down syndrome					
O Who are pre-or post-splenectomy, or with fund	ctional asplenia				

I confirm that the above details are correct:	
Signed:	Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:			
Name:	Name:			
Ward:	NHI:			
Pneumococcal (PCV13) conjugate vaccine - continued				
INITIATION – High risk individuals 5 years and over Re-assessment required after 4 doses				
Prerequisites (tick box where appropriate)				
O Up to an additional four doses (as appropriate) are funded for the (re-)immunisation of individuals 5 years and over with HIV, pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid leaks or primary immunodeficiency				
INITIATION – Testing for primary immunodeficiency diseases				
Prerequisites (tick box where appropriate)				
O For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician				
Note: Please refer to the Immunisation Handbook for the appropriate schedu	lle for catch up programmes			

I confirm that the above details are correct:

Signed:	Date:	
oigneu.	 Date.	